SMAD2 and hepatocellular carcinoma: The above results can preliminarily confirm that PFD can inhibit the activity of LX2 cells and the expression of TGF-β, thereby reducing the activation level of the TGF-β/Smad2 signaling pathway in HCCLM3 cells, thereby inhibiting the occurrence of EMT in HCC.